Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer-High Responder (MEGASET-HR) trial

• Main Authors: Jared C. Robins, M.D (Author), Andrew F. Khair, Ph.D., M.B.A (Author), Eric A. Widra, M.D (Author), Michael M. Alper, M.D (Author), Winnie W. Nelson, Pharm.D., M.S., M.B.A (Author), Eric D. Foster, Ph.D (Author), Anshul Sinha, B.Tech (Author), Masakazu Ando, Ph.D (Author), Patrick W. Heiser, Ph.D (Author), Gaurang S. Daftary, M.D., M.B.A (Author)
• Format: Book
• Published: Elsevier, 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: To determine the cost of achieving a live birth after first transfer using highly purified human menotropin (HP-hMG) or recombinant follicle-stimulating hormone (FSH) for controlled ovarian stimulation in predicted high-responder patients in the Menopur in Gonadotropin-releasing hormone A...